Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by chemotherapy followed by allo-SCT in eligible patients. However, following a flurry of drug approvals since 2017, the AML treatment landscape is undergoing a transformation. The entry of novel agents into the treatment paradigm will enable the increasingly personalized treatment of patients, based on the characteristics of their disease and specific biomarkers. However, several areas of unmet need remain. Notably, patients unfit for intensive chemotherapy induction and relapsed/refractory AML patients offer significant commercial opportunity for innovative agents.

Label expansions and new drug approvals (e.g., venetoclax, FLT3 inhibitors) will fuel substantial growth of the AML therapy market over the 2018-2028 forecast period. This report provides insight on how treatment options for AML are likely to change over the 2018-2028 forecast period. It also analyzes the current and future earnings potential of AML therapies.

Questions Answered:

  • How will first-generation FLT3 inhibitors (Rydapt) fare against second generation FLT3 inhibitors (Xospata, Vanflyta, crenolanib)? How do oncologists view this drug class? Which patient populations will be targeted?
  • How will Venclexta and Daurismo perform in the sizeable and highly lucrative newly diagnosed patient population ineligible for intensive treatment?
  • Will Mylotarg make a comeback in AML, despite its checkered approval history? How do oncologists currently view Mylotarg?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 17 country-specific interviews with thought-leading hematologist-oncologists.

Epidemiology: Diagnosed incident cases of de novo AML and AML with MDS-related changes (we do no estimates cases of therapy-related AML). Clinically and market-relevant drug -treatable populations, including: First-line AML, younger patients (aged < 60); first-line AML, older patients (aged ≥ 60); second-line AML, younger patients (aged < 60); second-line AML, older patients (aged ≥ 60); third-line AML

Forecast: 10-year, annualized drug-level sales and patient shares of key AML therapies through 2028, segmented by brands/generics and drug-treatable populations .

Emerging therapies: Phase III: 8 drugs; Phase I/II: 10 drugs.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Acute Myeloid Leukemia - Key Findings
    • Key Updates
      • December 2019
      • August 2019
      • June 2019
      • March 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Acute Myeloid Leukemia?
        • What Factors Are Constraining the Market for Acute Myeloid Leukemia?
      • Segment-Specific Trends
        • First-Line AML, Younger Patients (Aged <60)
        • First-Line AML, Older Patients (Aged ≥60)
        • Second-Line AML, Younger Patients (Aged <60)
        • Third-Line AML
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions - Acute Myeloid Leukemia (2018-2028) - December 2019
      • Market Forecast Dashboard - Acute Myeloid Leukemia (2018-2028) - December 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Disease Pathophysiology
      • Staging Systems in AML
      • Risk Stratification in AML
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • AML Transformation from Prior MDS
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Hypomethylating Agents
        • Antibody Drug Conjugates
        • FLT3 Inhibitors
        • Topoisomerase II Inhibitors
        • IDH Inhibitors
        • Apoptosis-Inducing Agents
        • Sonic Hedgehog Pathway Inhibitors
      • Medical Practice
        • First-Line AML, Older Patients (Aged ≥60)
        • First-Line AML, Younger Patients (Aged <60 Years)
        • Relapsed/Refractory AML
        • First-Line APL
        • Relapsed/Refractory APL
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in AML
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • FLT3 Inhibitors
        • Hypomethylating Agents
        • E-Selectin Inhibitors
        • HDAC Inhibitors
        • Apoptosis-Inducing Agents
        • NEDD8-Activating Enzyme Inhibitors
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Market Forecast Assumptions File
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Acute Myeloid Leukemia Bibliography

Author(s): Jorrit Schafer, M.Sc.,Ph.D; Atul Sharma, MPH

Jorrit Schäfer, , is a business insights analyst at Decision Resources Group. Prior to joining DRG, Dr. Schäfer worked as a postdoctoral research associate at Imperial College London, where he studied the impact of antibiotic stress on RNA repair in bacteria. Dr. Schäfer holds a in molecular medicine and a in molecular cell biology from Imperial College London.

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Related Reports

Acute Myeloid Leukemia | Current Treatment | Detailed, Expanded Analysis (US)

COMING SOON Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemothera...

View Details

Acute Myeloid Leukemia | Geographic Focus: China | Acute Myeloid Leukemia | China In-Depth | China

Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Histor...

View Details

Acute Myeloid Leukemia | Epidemiology | Mature Markets

DRG Epidemiology's coverage of acute myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence...

View Details

Acute Myeloid Leukemia | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia...

View Details